CY1111078T1 - Αντικαρκινικες ενωσεις κυκλοπεντα[g]κιναζολινων - Google Patents
Αντικαρκινικες ενωσεις κυκλοπεντα[g]κιναζολινωνInfo
- Publication number
- CY1111078T1 CY1111078T1 CY20111100015T CY111100015T CY1111078T1 CY 1111078 T1 CY1111078 T1 CY 1111078T1 CY 20111100015 T CY20111100015 T CY 20111100015T CY 111100015 T CY111100015 T CY 111100015T CY 1111078 T1 CY1111078 T1 CY 1111078T1
- Authority
- CY
- Cyprus
- Prior art keywords
- alkyl
- halogenoalkyl
- cyanoalkyl
- hydroxyalkyl
- alkynyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Non-Alcoholic Beverages (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Κυκλοπεντα[g]κιναζολίνες του τύπου (I) όπου: το Α είναι μια ομάδα OR ή NR0R1 όπου τα R0 και R1 είναι το καθένα ανεξάρτητα υδρογόνο, C1-4 αλκυλο, C3-4 αλκενυλο, C3-4 αλκινυλο, C2-4 υδροξυαλκυλο, C2-4 αλογονοαλκυλο ή C1-4 κυανοαλκυλο, ή τα R0 και R1 μαζί με το ενδιάμεσο Ν σχηματίζουν έναν πεντα- ή εξαμελή ετεροκυκλικό δακτύλιο· το p είναι ακέραιος μεταξύ 1 και 4· το R2 είναι υδρογόνο, C1-4 αλκυλο, C3-4 αλκενυλο, C3-4 αλκινυλο, C2-4 υδροξυαλκυλο, C2-4 αλογονοαλκυλο ή C1-4 κυανοαλκυλο· το Ar1 είναι φαινυλένο, θειοφαινοδιυλο, θειαζολοδιυλο, πυριδινοδιυλο ή πυριμιδινοδιυλο που μπορεί να φέρει προαιρετικώς έναν ή δύο υποκαταστάτες που επιλέγονται από αλογόνο, υδροξύλιο, αμινο, νίτρο, κυανό, τριφθορομεθυλο, C1-4 αλκυλο και C1-4 αλκοξυ· και το R3 είναι μια ομάδα των παρακάτω τύπων: -A1-Ar2-A2-Y1-A5-CON(R)CH(Y4)Y5-A8-X-Ar4 και φαρμακευτικώς αποδεκτά άλατα ή εστέρες αυτών έχουν θεραπευτική αξία ιδιαίτερα στη θεραπεία του καρκίνου.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0121151A GB0121151D0 (en) | 2001-08-31 | 2001-08-31 | Anti-cancer compounds |
| GB0129387A GB0129387D0 (en) | 2001-12-07 | 2001-12-07 | Anti-cancer compounds |
| US34025301P | 2001-12-18 | 2001-12-18 | |
| EP02755281A EP1421105B1 (en) | 2001-08-31 | 2002-08-30 | Anti-cancer cyclopenta¬g quinazoline compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1111078T1 true CY1111078T1 (el) | 2015-06-11 |
Family
ID=27256270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20111100015T CY1111078T1 (el) | 2001-08-31 | 2011-01-04 | Αντικαρκινικες ενωσεις κυκλοπεντα[g]κιναζολινων |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US7297701B2 (el) |
| EP (3) | EP2311850A1 (el) |
| JP (1) | JP4328202B2 (el) |
| KR (2) | KR20100043294A (el) |
| AT (1) | ATE483722T1 (el) |
| AU (1) | AU2002321576B2 (el) |
| BR (1) | BRPI0212215B8 (el) |
| CA (1) | CA2458813C (el) |
| CY (1) | CY1111078T1 (el) |
| DE (1) | DE60237902D1 (el) |
| DK (1) | DK1421105T3 (el) |
| MX (1) | MXPA04001905A (el) |
| PT (1) | PT1421105E (el) |
| WO (1) | WO2003020748A1 (el) |
| ZA (1) | ZA200401587B (el) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1421105E (pt) * | 2001-08-31 | 2010-12-07 | Btg Int Ltd | Compostos anticancerígenos de ciclopenta-g quinazolina |
| GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
| AU2007262635B2 (en) | 2006-06-23 | 2014-09-11 | Adc Therapeutics Sa | Polynucleotides and polypeptide sequences involved in cancer |
| ES2387334T3 (es) * | 2008-03-18 | 2012-09-20 | Btg International Limited | Derivados de ciclopenta[g]quinazolina para el tratamiento de la artritis reumatoide o la leucemia mielocítica aguda |
| AU2009321508B2 (en) | 2008-11-03 | 2015-03-12 | Adc Therapeutics Sa | Antibodies that specifically block the biological activity of a tumor antigen |
| WO2012011939A2 (en) | 2010-07-19 | 2012-01-26 | Onyx Pharmaceuticals, Inc. | Synthesis of cyclopentaquinazolines |
| HUE028918T2 (en) * | 2010-12-22 | 2017-01-30 | Btg Int Ltd | Effective peptide couplings and their use in the synthesis and isolation of cyclopenta (G) quinazoline trinodium salt |
| MX352373B (es) | 2011-03-31 | 2017-11-22 | Adc Therapeutics Sa | Anticuerpos contra antigeno 1 asociado con riñon y sus fragmentos de union de antigeno. |
| CA3115623A1 (en) | 2012-01-09 | 2013-07-18 | Adc Therapeutics Sa | Method for treating breast cancer |
| GB201707864D0 (en) * | 2017-05-16 | 2017-06-28 | Inst Of Cancer Research: Royal Cancer Hospital | Platinum-reistant cancer treatment |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2065653B (en) | 1979-12-19 | 1983-03-09 | Nat Res Dev | Anti-cancer quinazoline derivatives |
| GB8607683D0 (en) | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
| GB9205320D0 (en) | 1992-03-11 | 1992-04-22 | Ici Plc | Anti-tumour compounds |
| GB9223352D0 (en) * | 1992-11-06 | 1992-12-23 | Ici Plc | Tricyclic compounds |
| GB9408936D0 (en) | 1994-05-05 | 1994-06-22 | Cancer Res Inst | Anti-cancer compounds |
| JPH1166841A (ja) * | 1997-08-22 | 1999-03-09 | Mitsubishi Electric Corp | 半導体記憶装置 |
| KR100303775B1 (ko) * | 1998-10-28 | 2001-09-24 | 박종섭 | 디디알 에스디램에서 데이터스트로브신호를 제어하기 위한 방법및 장치 |
| GB9904275D0 (en) | 1999-02-24 | 1999-04-21 | Cancer Res Campaign Tech | Anti-cancer compounds |
| JP3416083B2 (ja) * | 1999-08-31 | 2003-06-16 | 株式会社日立製作所 | 半導体装置 |
| JP2002007200A (ja) * | 2000-06-16 | 2002-01-11 | Nec Corp | メモリ制御装置及び動作切替方法並びにインターフェース装置、半導体集積チップ、記録媒体 |
| PT1421105E (pt) * | 2001-08-31 | 2010-12-07 | Btg Int Ltd | Compostos anticancerígenos de ciclopenta-g quinazolina |
| PT1420809E (pt) | 2001-08-31 | 2012-01-03 | Btg Int Ltd | Utilização de derivados de ciclopenta[g]quinazolina para tratamento de cancro |
| KR100568546B1 (ko) * | 2004-10-19 | 2006-04-07 | 삼성전자주식회사 | 메모리 시스템, 반도체 메모리 장치, 및 이 시스템과장치의 출력 데이터 스트로우브 신호 발생 방법 |
| KR100755371B1 (ko) * | 2005-05-03 | 2007-09-04 | 삼성전자주식회사 | 반도체 메모리 장치 및 이 장치의 데이터 스트로우브 신호발생방법 |
-
2002
- 2002-08-30 PT PT02755281T patent/PT1421105E/pt unknown
- 2002-08-30 EP EP10185923A patent/EP2311850A1/en not_active Withdrawn
- 2002-08-30 DK DK02755281.9T patent/DK1421105T3/da active
- 2002-08-30 BR BRPI0212215A patent/BRPI0212215B8/pt not_active IP Right Cessation
- 2002-08-30 CA CA2458813A patent/CA2458813C/en not_active Expired - Lifetime
- 2002-08-30 EP EP02755281A patent/EP1421105B1/en not_active Expired - Lifetime
- 2002-08-30 AT AT02755281T patent/ATE483722T1/de active
- 2002-08-30 JP JP2003525018A patent/JP4328202B2/ja not_active Expired - Lifetime
- 2002-08-30 AU AU2002321576A patent/AU2002321576B2/en not_active Expired
- 2002-08-30 DE DE60237902T patent/DE60237902D1/de not_active Expired - Lifetime
- 2002-08-30 US US10/487,871 patent/US7297701B2/en not_active Expired - Lifetime
- 2002-08-30 WO PCT/GB2002/003979 patent/WO2003020748A1/en active Application Filing
- 2002-08-30 MX MXPA04001905A patent/MXPA04001905A/es active IP Right Grant
- 2002-08-30 EP EP10177988A patent/EP2332962A1/en not_active Withdrawn
- 2002-08-30 KR KR1020107007266A patent/KR20100043294A/ko not_active Application Discontinuation
- 2002-08-30 KR KR1020047002994A patent/KR100983962B1/ko active IP Right Grant
-
2004
- 2004-02-26 ZA ZA2004/01587A patent/ZA200401587B/en unknown
-
2007
- 2007-02-27 US US11/710,985 patent/US7863284B2/en active Active
- 2007-03-26 US US11/727,242 patent/US7705006B2/en not_active Expired - Lifetime
-
2009
- 2009-11-02 US US12/588,910 patent/US8486955B2/en active Active
-
2010
- 2010-03-03 US US12/659,286 patent/US8063056B2/en not_active Expired - Lifetime
- 2010-06-29 US US12/801,853 patent/US8552016B2/en not_active Expired - Lifetime
-
2011
- 2011-01-04 CY CY20111100015T patent/CY1111078T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1111078T1 (el) | Αντικαρκινικες ενωσεις κυκλοπεντα[g]κιναζολινων | |
| CY1112143T1 (el) | Χρηση παραγωγων kykλοπenta[g]kinαζολινης για θεραπεια καρκινου | |
| EP1243582A4 (en) | CHINOLINE AND CHINAZOLINE DERIVATIVES AND MEDICATIONS CONTAINING THEM | |
| NO983970D0 (no) | Tricykliske forbindelser, deres fremstilling og anvendelse | |
| TR200102237T2 (tr) | N²-fenil amidin türevleri. | |
| WO2002018383A3 (en) | Aza heterocyclic derivatives and their therapeutic use | |
| WO2003106428A8 (fr) | Derives d'arylsulfonamides et leur utilisation en tant que antagonistes au recepteur b1 de la bradykinine | |
| BR0100318A (pt) | Compostos de uracila e uso dos mesmos | |
| PE20011166A1 (es) | Piridinas, pirimidinas, purinonas, pirrolopirimidinonas y pirrolopiridinonas como antagonistas del factor liberador de corticotropina | |
| PT1140851E (pt) | 4-oxo-1,4-di-hidro-3-quinolinacarboxamidas como agentes antivirais | |
| WO2005115984A3 (en) | Large conductance calcium-activitated k channel opener | |
| TW200744575A (en) | Methods of treating epileptogenesis | |
| MY138156A (en) | Carbamate compounds for use in preventing or treating neurodegenerative disorders | |
| YU67703A (sh) | Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju poremećaja kretanja | |
| TR200001950T2 (tr) | İkameli 2-benzilamino-2-fenil-asetamid bileşikler. | |
| BR0114812A (pt) | Derivados de 2-pirimidinilóxi-n-aril-benzilamina, seus processos de preparo e uso | |
| NO895023D0 (no) | Fremgangsmaate for fremstilling av terapeutisk aktive aminderivater. | |
| HK1062270A1 (en) | Carbamate compounds for use in preventing or treating anxiety disorders | |
| RS67503A (en) | Carbamate compounds for use in preventing of treating psychotic disorders | |
| PE20010649A1 (es) | Derivados de antranilamida de piperidinas 1,4-di-sustituidas como antagonistas muscarinicos | |
| BRPI0418375A (pt) | derivados de diaza-espiropiperidina | |
| DE602006020458D1 (de) | Carbonsäureamidverbindung und deren verwendung | |
| PE20040693A1 (es) | N-sulfonilaminotiazol como mediadores de la sulfatasa de esteroides | |
| MY136733A (en) | Carbamate compounds for use in preventing or treating psychotic disorders | |
| TH27168A (th) | อนุพันธ์กรด ไพริมิดินิลอะคริลิค |